Praxis Precision Medicines stopped its registrational EMBOLD trial early after an interim analysis showed strong efficacy for relutrigine in genetic developmental and epileptic encephalopathies. The company reported that predefined stopping rules were met and said the data will form the backbone of upcoming regulatory discussions with the FDA. The early stop led to a sharp market reaction and renewed investor focus on small‑molecule sodium channel modulators for severe epilepsies. Regulators will now evaluate the full dataset and the company’s plan for a submission; the speed and magnitude of the efficacy signal will shape approval timing and labeling negotiations.